Safety, Reactogenicity, and Immunogenicity of a Tetravalent Meningococcal Polysaccharide–Diphtheria Toxoid Conjugate Vaccine Given to Healthy Adults
Open Access
- 15 December 2002
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 186 (12) , 1848-1851
Abstract
Healthy adults, 18–55 years old, were immunized once with a tetravalent (serogroups A, C, Y, and W-135) meningococcal vaccine conjugated to diphtheria toxoid at 1 of 3 doses and were monitored for safety, reactogenicity, and immunogenicity. No immediate reactions were observed. Only 1 of 89 subjects reported fever; only 1 reported any severe reactogenicity (local pain/soreness, chills, arthralgia, anorexia, and malaise). For each serogroup and in each dose group, the geometric mean serum bactericidal antibody (SBA) titer and immunoglobulin G concentration increased after immunization. In the 4- and 10-μg–dose groups, all subjects had SBA titers ⩾8 against serogroups A and C, and 89% and 93% of subjects had SBA titers ⩾8 against serogroups Y and W-135, respectively. The A, C, Y, and W-135 Neisseria meningitidis–diphtheria toxoid conjugate vaccine, when given to healthy adults as a single intramuscular injection of 1, 4, or 10 μg/serogroup, is acceptably tolerated and immunogenic and deserves further developmentKeywords
This publication has 10 references indexed in Scilit:
- Invasive Meningococcal Disease in Adolescents and Young AdultsJAMA, 2001
- Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United StatesVaccine, 2001
- Influence of Prior Meningococcal C Polysaccharide Vaccination on the Response and Generation of Memory after Meningococcal C Conjugate Vaccination in Young ChildrenThe Journal of Infectious Diseases, 2001
- Serological Basis for Use of Meningococcal Serogroup C Conjugate Vaccines in the United Kingdom: Reevaluation of Correlates of ProtectionInfection and Immunity, 2001
- Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infantsThe Pediatric Infectious Disease Journal, 2001
- Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in EnglandThe Lancet, 2001
- Meningococcal C Polysaccharide Vaccine Induces Immunologic Hyporesponsiveness in Adults That Is Overcome by Meningococcal C Conjugate VaccineThe Journal of Infectious Diseases, 2000
- Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adultsVaccine, 1999
- Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study GroupClinical and Diagnostic Laboratory Immunology, 1997
- Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assayJournal of Clinical Microbiology, 1992